Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Research & Development (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Research & Development for 15 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 14.77% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.6 million, a 31.86% decrease, with the full-year FY2024 number at $10.6 million, up 9.18% from a year prior.
  • Research & Development was $2.4 million for Q3 2025 at Plus Therapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.0 million in Q4 2022 to a low of $1.1 million in Q2 2021.
  • A 5-year average of $2.4 million and a median of $2.5 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 343.75% in 2021, then crashed 55.07% in 2025.
  • Plus Therapeutics' Research & Development stood at $1.5 million in 2021, then soared by 300.67% to $6.0 million in 2022, then crashed by 53.23% to $2.8 million in 2023, then fell by 21.76% to $2.2 million in 2024, then grew by 11.44% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Research & Development are $2.4 million (Q3 2025), $1.2 million (Q2 2025), and $1.8 million (Q1 2025).